Kuros Biosciences AG Share Price Swiss Exchange
Equities
CH0011025217
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CHF | - |
24/04 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
17/04 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 1.8Cr 1.98Cr 164.83Cr | Sales 2023 | 3.36Cr 3.69Cr 307.59Cr | Capitalization | 13Cr 14Cr 1.18TCr |
---|---|---|---|---|---|
Net income 2022 | -1.4Cr -1.54Cr -128.3Cr | Net income 2023 | -1.3Cr -1.43Cr -119.14Cr | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 2.21Cr 2.43Cr 202.39Cr | Net cash position 2023 | 1.2Cr 1.32Cr 109.95Cr | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.77% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17/23/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 14/18/14 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 11TCr | |
+11.84% | 10TCr | |
-14.15% | 2.24TCr | |
-1.05% | 2.23TCr | |
-5.29% | 1.91TCr | |
-38.29% | 1.8TCr | |
-4.16% | 1.79TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.25TCr |